Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9573 posts found.

exelixis_hq_web

Exelixis’ Cabometyx smashes Pfizer cancer drug in Phase II trial

October 11, 2016 Manufacturing and Production, Research and Development Cabometyx, Exelixis, Pfizer, Phase II, Sutent, advanced renal cell carcinoma

Phase II results presented by genomics-based discovery company  Exelixis at the European Society for Medical Oncology (ESMO) congresss has put …
News
takeda_world

Takeda enters $790m cancer development deal

October 11, 2016 Manufacturing and Production, Research and Development Cancer, Crescendo Biologics, Takeda, clinical partnership, humabody

Takeda and Crescendo Biologics have shaken hands on a $790 million deal to develop and commercialise cancer therapeutics using Crescendo’s …
News
teva-kim-innes-250

New UK & Ireland general manager for Teva

October 10, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Teva, appointment

Kim Innes has been appointed by Teva as its new general manager of UK & Ireland. Innes succeeds Richard Daniell, …
Appointment
shutterstock_142740349_resize_3

Educating pharma

October 10, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing educated, funding, medical education, transparency

Originally published in the October issue of Pharmafocus, Sean Murray takes a look at how pharma continues to occupy a key …
Feature
opdivo_1_1

Failure for BMS’ Opdivo in lung cancer trial

October 10, 2016 Research and Development, Sales and Marketing BMS, MSD, Roche, clinical trial failure, keytruda, opdivo, tecentriq

Disappointing news for Bristol-Myers Squibb as the company announced that its blockbuster drug Opdivo (nivolumab) failed to meet its primary …
News
roche__tree

Roche’s lung cancer success spells competition for BMS’ Opdivo

October 10, 2016 Research and Development, Sales and Marketing BMS, Roche, lung cancer, opdivo, tecentriq

Roche’s immune-system booster drug Tecentriq (atezolizumab) may cause trouble in the lung cancer field for leader Bristol-Myers Squibb’s Opdivo according …
News

“Incorrect classification” of EpiPen leads to $1 billion bill for US government

October 6, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cost, Heather Bresch, Misclassification, Mylan, Price hike, classification, epipen, price, scandal

Mylan’s EpiPen woes show no sign of abating after CMS (Centers for Medicare and Medicaid Services) released figures that show …
News
sicorbio

Teva to sell Allergan’s UK & Ireland generics business for $770m

October 6, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, Teva

Teva has announced that it is set to sell Allergan’s UK and Ireland-based generics business for $770 million.
News
alnylambuilding-750xx1632-918-0-153

Alnylam’s shares plunge by 42% after deaths in clinical trials

October 6, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alnylam, Shares, clinical trials, deaths, failure, market value, phase III, revusiran

Alnylam Pharmaceuticals’ shares lost close to half of their value as it was forced to end a trial of its …
News
basel_site

Novartis axes 175 jobs globally in operations reshuffle

October 5, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Novartis has announced it is to shut down parts of its research operations in Switzerland and China and cutting 175 …
News
1511671_logo_1456919640

Merck’s Keytruda suffers rejection at hands of NICE

October 5, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing MSD, Merck, NHS, NICE, keytruda

NICE rejected Merck’s Keytruda, a treatment for advanced non-small-cell lung cancer (NSCLC), on the basis that the drug was not …
News
astrazeneca_plaque

AZ “disappointment” at heart drug failure

October 5, 2016 Research and Development AZ, AstraZeneca, trial failure

AstraZeneca has expressed its disappointment that its heart drug Brilinta (ticagrelor) failed to meet its primary endpoint in a recent …
News
fda_sign_web

FDA warns that certain hepatitis C drugs can have serious side-effects

October 5, 2016 Medical Communications, Research and Development FDA, hepatitis B, hepatitis C

The FDA has issued a warning to patients who are currently taking drugs to treat hepatitis C that they may …
News
1280px-epi-pen_1

Mylan’s promised half-price EpiPen not available until year’s end

October 5, 2016 Research and Development, Sales and Marketing Mylan, epipen

Consumers may have to wait until the end of the year for the half-price EpiPen, months after Mylan originally promised …
News

Roche granted breakthrough therapy designation by FDA

October 5, 2016 Research and Development Actemra, FDA, Giant Cell arteritis, Roche, breakthrough therapy

Roche has announced that the FDA has granted its Actembra drug breakthrough therapy designation for giant cell arteritis. The breakthrough …
News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025